Hims & Hers Health Inc. is trading 4.5% down at $26.27 as investors react to the company's recently completed acquisition of Australian telehealth platform Eucalyptus.
- The decline is being attributed to company-specific factors, primarily concerns over the $1.15 billion price tag for the Eucalyptus acquisition, which was formally closed on June 2.
- Investors are also weighing the potential for significant shareholder dilution, as the deal was partly funded with $350 million in convertible debt.
- While major U.S. benchmarks are mixed to slightly down, analysis suggests the HIMS selloff is driven by these specific strategic and financial considerations rather than a broad market trend.